SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

A stronger-than-expected quarterly report, raised outlook and record backlog have revived confidence in CoreWeaves AI-compute demand, while managements emphasis on customer prepayments and contract-backed financing addressed some funding concerns. Traders are broadly bullish and discussing a possible short squeeze, but skeptics remain focused on heavy debt, interest costs, capital spending and the path to sustainable profitability.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists Q3 results and earnings call are drawing attention, with traders focused on improved profitability and margins, Samsung licensing revenue, and expected recurring Samsung and Micron payments alongside stronger Q4 operating income. Sentiment is broadly bullish on the financial turnaround and AI-memory growth plans, though some question the reported results versus lofty estimates, lower product sales, and the lack of concrete SK Hynix or Nasdaq updates.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRSP is drawing attention after a sharp selloff despite encouraging CTX310 data showing substantial triglyceride reductions. Traders are debating whether the decline reflects skepticism toward early-stage results or an overreaction, while some point to CASGEVYs ongoing commercial sales as a counterweight.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigettis Q3 results missed expectations, intensifying selling and concerns that its high valuation is outpacing commercial revenue and profitability. Bears question its business prospects and commercialization timeline, while bulls point to quantum-technology progress and argue the companys long-term potential outweighs near-term results.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumbles Q3 earnings are the focus, with bullish traders looking for Northern Data/Quake AI revenue and evidence that the reported Anthropic compute agreement can translate into growth; many also point to high short interest as potential fuel for a squeeze. Skeptics question the agreements confirmation, data-center financing and dilution risks, so expectations are sharply divided.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Bridgewater, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech shares are under pressure after its results and outlook highlighted slower-than-expected U.S. uptake of CARVYKTI, despite continued overall growth and a return to profitability. Traders debate whether the selloff is an overreaction or reflects softer near-term growth expectations; bullish voices point to international expansion and upcoming in-vivo CAR-T data.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

On Holdings Q3 reportrecord sales and an earnings beat, but unchanged full-year growth guidancehas been followed by a sharp selloff. Traders question the quality of the results, citing tariff refunds boost to margins and concerns about direct-to-consumer momentum, while some view the decline as a buying opportunity.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors Q3 call reaffirmed that deramiocels application for Duchenne muscular dystrophy is in final FDA review ahead of the November 22 decision, keeping the upcoming regulatory ruling at the center of discussion. Many traders took managements confidence and launch preparations as encouraging, while others stressed that approval is uncertain given the FDA advisory committees earlier concerns and the binary nature of the decision; the share decline also prompted debate over earnings and market trading.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. The firm offers annealing and gate-model quantum computing technologies. It provides professional services that assist customers in identifying and implementing quantum computing applications and selling quantum computer systems to customers. The company was founded by Eric Ladizinsky in 1999 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Waves Q3 results are driving attention, with shares selling off despite revenue growth as traders focus on softer bookings, high costs and the gap between its small current revenue base and lofty valuation. Bulls point to a sharply higher backlog and growing commercial deployments, while skeptics question when those orders will convert into meaningful revenue and profitability.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Uncertainty over DefenCaths post-TDAPA reimbursement and adoption is driving attention, after DaVita warned that reimbursement could decline through 2027 and the stock sold off. Traders disagree on whether that signals weaker sales: CMS set the Q1 2027 add-on at $8.32 per treatment, while future quarterly rates and uptake remain uncertain; a Fresenius observational comparison with ClearGuard has added to the debate.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


Hoyos879

Hoyos Engineering